ΨΥΧΟΛΟΓΙΑ - Έρευνα και Εφαρμογές ΤΕΥΧΟΣ 4ο | страница 69

ΙSSN: 2623- 3673
Φεβρουάριος, 2019
Ψυχολογία :έρευνα & εφαρμογές
51. Andrade C. J Clin Psychiatry. 2016 Nov;77(11):e1491-e1494.Use of
Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know
Safety Issues.
52. Li Q, Guo D, Yang H, Ye Z, Huang J, Shu Y. Basic Clin Pharmacol
Toxicol. 2017 Jun;120(6):601-609. Metabolic Response to Olanzapine in
Healthy Chinese Subjects with rs7093146 Polymorphism in Transcription Factor
7-like 2 Gene (TCF7L2): A Prospective Study.
53. Li H, Fang M, Xu M, Li S, Du J, Li W, Chen H. PLoS One. 2016 Dec
14;11(12):e0167930. Chronic Olanzapine Treatment Induces Disorders of
Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for
Olanzapine-Induced Insulin Resistance.
54. Franch Pato C, Molina Rodríguez V, Franch Valverde J. Rev Psiquiatr Salud
Ment. 2017 Jan - Mar;10(1):38-44 Metabolic syndrome and atypical
antipsychotics: Possibility of prediction and control.
55 . Misiak B, Laczmanski L, Sloka N, Szmida E, Slezak R, Piotrowski P,
Kiejna A, Frydecka D. Int J Neuropsychopharmacol. 2017 Mar 1;20(3):207-
212. Genetic Variation in One-Carbon Metabolism and Changes in Metabolic
Parameters in First-Episode Schizophrenia Patients.
56. Bruno A, Pandolfo G, Crucitti M, Maisano A, Zoccali R, Muscatello M. J
Nutr Biochem. 2017 Feb;40:32-35 Metabolic outcomes of bergamot
polyphenolic fraction administration in patients treated with second-generation
antipsychotics: a pilot study.
57. Suvitaival T, Mantere O, Kieseppä T, Mattila I, Pöhö P, Hyötyläinen T,
Suvisaari J, Orešič M. Transl Psychiatry. 2016 Nov 15;6(11):e951. Serum
metabolite profile associates with the development of metabolic co-morbidities
in first-episode psychosis.
58. Tarraf C, Naja W. Prim Care Companion CNS Disord. 2016 Aug 25;18(4).
Aripiprazole-Induced Hyperlipidemia: An Update.
59. Durgam S, Greenberg W, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R,
Volk S. Psychopharmacology (Berl). 2017 Jan;234(2):199-209. Safety and
tolerability of cariprazine in the long-term treatment of schizophrenia: results
from a 48-week, single-arm, open-label extension study.
60. Andrade C. J Clin Psychiatry. 2016 Oct;77(10):1362-1364. Metformin as a
Possible Intervention for Cardiometabolic Risks in Pediatric Subjects Exposed to
Antipsychotic Drugs.
61. Andrade C.
J Clin Psychiatry. 2016 Sep;77(9):e1090-e1094.
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3:
Psychopharmacological Interventions.
62. Wu R, Zhang F, Gao K, Ou J, Shao P, Jin H, Guo W, Chan P, Zhao J. Mol
Psychiatry. 2016 Nov;21(11):1537-1544. Metformin treatment of antipsychotic-
induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
63. Ishøy P, Knop F, Broberg B, Bak N, Andersen U, Jørgensen N, Holst J,
Glenthøj B, Ebdrup B. Diabetes Obes Metab. 2017 Feb;19(2):162-171. Effect of
GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated
patients with schizophrenia: a randomized, placebo-controlled trial.